Close Menu

NEW YORK (GenomeWeb) – Shares of Exact Sciences tumbled nearly 15 percent on Wednesday as investors were spooked by a study abstract that presented data suggesting a liquid biopsy test for colorectal cancer screening could rival the performance of Exact Science's Cologuard test.

Industry analysts, however, were not convinced that the new test should be considered a competitive threat yet, and many said the dip in Exact Sciences' stock price represented a buying opportunity.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.